Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

Combivent generic equivalent?
Guselkumab brand name?
What is the difference between apixaban and apixaban accord?
Prolia and osteonecrosis?
Drugpatentwatch market analysis industry today?

Prescribing soliqua 100 33?

Soliqua® (Insulin glargine/Lispro)
Soliqua 100/33 – 100 U/mL glargine + 33 U/mL lispro

1. Indication & Approvals

  • Indicated for the treatment of type 2 diabetes mellitus (T2DM) in adults when basal–bolus insulin therapy is required.
  • Not indicated for type 1 diabetes, gestational diabetes, or for use in patients who are unable to use basal‑bolus insulin regimens.

2. General Prescribing Information

Item Typical Guidance
Starting dose 10 U once daily (usually at the same time each day, e.g., evening)
Titration Increase by 2–4 U weekly based on fasting plasma glucose (FPG) targets. Common target: 80–130 mg/dL (4.4–7.2 mmol/L).
Maximum dose Generally ≤50 U/day, but individualized per patient response and safety.
Dose adjustment Adjust the basal (glargine) component based on fasting glucose; adjust the bolus (lispro) component based on pre‑meal or post‑meal glucose.
Injection timing Basal insulin (glargine) once daily at a consistent time. Lispro is a mealtime insulin (≤30 min before or up to 1 h after the start of a meal).
Sites Abdominal wall, thighs, buttocks, and upper arms. Rotate sites within the same region.
Storage Store unopened pens in a refrigerator (2–8 °C). Once opened, store at room temperature (≤25 °C) for up to 28 days (do not freeze).
Duration of use As needed for glycemic control; no defined maximum duration.

3. Contraindications & Precautions

Category Key Points
Contraindications Known hypersensitivity to insulin or any component, active insulin allergy.
Precautions • Hypoglycemia risk – especially in patients with renal/hepatic impairment, elderly, or those on other hypoglycemics.
• Lipodystrophy – monitor for lipohypertrophy at injection sites; rotate sites.
• Pregnancy & lactation – use only if benefits outweigh risks; consult obstetric guidelines.
Drug Interactions • Sulfonylureas, meglitinides, or other insulin may potentiate hypoglycemia.
• Alcohol, beta‑blockers, and certain diuretics can mask hypoglycemia symptoms.

4. Common Adverse Reactions

Category Frequency (≈)
Hypoglycemia Most frequent; monitor and educate patients on recognition and treatment.
Injection site reactions Mild erythema, pruritus, lipodystrophy.
Weight gain Often seen with insulin therapy.
Rare Angioedema, anaphylaxis (very rare).

5. Monitoring & Follow‑Up

Parameter Frequency Target
HbA1c Every 3–6 months <7% (or individualized)
Fasting Plasma Glucose 2–3 days before each visit or per clinic protocol 80–130 mg/dL (4.4–7.2 mmol/L)
Post‑prandial Glucose As needed ≤180 mg/dL (10 mmol/L)
Weight Each visit Monitor for excessive gain
Renal & Hepatic Function Every 6–12 months or as clinically indicated Baseline, then annually

6. Patient Education Highlights

  • Injection technique: Use the attached syringe/pen, pre‑test insulin activity by checking the vial/pen, inject into the skin (not subcutaneously into the fat layer) and always rotate sites.
  • Timing: Basal once daily; lispro 0–30 min before or within 1 h after the start of a meal.
  • Hypoglycemia: Recognize symptoms (sweating, shakiness, confusion) and treat with fast‑acting carbohydrates (glucose tablets, juice).
  • Missed dose: If a basal dose is missed, do not double the next dose; follow the “missed dose” guidance on the patient education sheet.
  • Storage & handling: Keep the pen out of direct sunlight and away from heat; avoid freezing.
  • Record keeping: Keep a log of doses, blood glucose readings, and any symptoms.

7. Key Points for the Prescriber

  1. Start low, titrate slowly to minimize hypoglycemia.
  2. Use the same time each day for basal dose to maintain consistency.
  3. Educate the patient on insulin self‑management, safety, and troubleshooting.
  4. Review renal/hepatic function periodically; adjust dosing as needed.
  5. Check for other medications that might increase hypoglycemia risk.
  6. Document any adverse events and adjust the regimen accordingly.

Final Note

This overview is for educational purposes only and should not replace individualized clinical judgment or the official prescribing information (e.g., the FDA label or manufacturer’s package insert). Always consult the most current product literature, local guidelines, and the patient’s medical history before initiating or adjusting therapy.



Other Questions About Soliqua :

Patent status soliqua sanofi? Generic soliqua? Patent status soliqua sanofi europe? Soliqua 100/33 initiation? Soliqua 100 33 insulin combination therapy? Soliqua 100 33 coupon? Medicines in soliqua 100 33?